Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US

Rhea-AI Summary

On September 16, 2020, the Novartis US Foundation announced a USD 25 million commitment to tackle health inequities in underserved communities in the United States, particularly focusing on diversity in clinical trials. This funding is aimed at fostering partnerships and enhancing healthcare access amidst the ongoing challenges of the COVID-19 pandemic and racial disparities. Previously, the foundation had committed over USD 10 million to support healthcare systems in overcoming barriers to care. The foundation also seeks to address the underrepresentation of minorities in clinical trials.

Positive

• USD 25 million commitment to improve health equity.
• Focus on enhancing diversity in clinical trials, addressing underrepresentation.
• Previous USD 10 million investment in healthcare partnerships.

Negative

• None.

EAST HANOVER, N.J., Sept. 16, 2020 /PRNewswire/ -- Today the Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and programs that address health inequities, with a focus on diversity in clinical trials, in the United States. This commitment reinforces the Novartis US Foundation mission to improve health in underserved communities in the United States by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system.

"In the wake of the COVID-19 pandemic and heightened attention on racial injustice in the US, there has been new and significant recognition of disparities in care in minority communities. We have accelerated our commitment to create innovative and sustainable partnerships that have the potential to improve health equity in underserved communities, including African American/Black and Hispanic communities," said Tom Kendris, US Country President, Novartis Corporation, Chairman, Board of Trustees, Novartis US Foundation.

Since re-focusing its mission last year, the Novartis US Foundation has committed more than USD 10 million to develop partnerships to enable healthcare systems to better meet the needs of their patients by addressing barriers to care, or by identifying changes needed to address the underlying causes of health disparities. This support included signature partnerships with New Jersey Primary Care Association, The CDC Foundation, Institute for Healthcare Improvement and USD 5 million to support COVID-19 response efforts, including 40 grants to support local communities.

A key area of focus for the additional commitment will be in addressing the vast underrepresentation of minorities, including Black Americans, in clinical trials. In 2019, African Americans/Blacks made up 13.5% of the US population, but only 9% of clinical trial participants^1,2. Diversity in clinical trials is critical to understanding how medicines will work in all patient populations impacted by the disease.

"We believe the Novartis US Foundation can serve as a catalyst for change through a multi-year, multi-million dollar commitment. As part of this effort, we will collaborate with partners and support industry-wide programs to improve diversity in clinical trials through systemic and policy-driven solutions that go beyond calls to study sponsors to be more inclusive," continued Kendris.

There are several barriers to clinical trial participation reflective of other systemic issues leading to disparities in health such as, mistrust of the healthcare system, a lack of comfort or understanding of health systems, including clinical trial processes, as well as time and resource constraints associated with participation³. The US Foundation is in the exploration phase to identify all dimensions of these issues and to identify new collaborators from the public, private and advocacy sectors. 

About Social Determinants of Health and Health Disparities
CDC defines social determinants of health as the conditions – social, economic and physical – in places where people live, learn, work and play that influence health outcomes of people². These conditions may include safe and affordable housing, access to education, food security, and clean environments². When health outcomes are better or worse from one population to the next, there is disparity. Health disparities have impacts reaching far beyond those directly affected by limiting advancements in care and resulting in avoidable costs³. For example, the American Public Health Association found racial disparities in health led to an estimated $93 billion in excess medical care costs and $42 billion in lost productivity⁴.

About the Novartis US Foundation
The Novartis US Foundation is a 501(c)(3) charitable foundation established by Novartis to support philanthropic efforts in the United States. The mission of the Novartis US Foundation is to improve health in underserved communities in the United States by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system. We do this by supporting sustainable programs and partnerships that strengthen health systems, eliminate barriers to quality health services, and enhance local communities.

About Novartis
Located in East Hanover, NJ Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs about 15,000 people in the United States. For more information, please visit https://www.novartis.us.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library 
For questions about the site or required registration, please contact media.relations@novartis.com.

References

1. US Food and Drug Administration. 2019 Drug Trials Snapshots Summary Report. Available at: https://www.fda.gov/media/135337/download. Accessed August 27, 2020.
2. US Census Bureau. Quick Facts. Available at: https://www.census.gov/quickfacts/fact/table/US/RHI225219. Accessed August 27, 2020.
3. Clark, LT, Watkins, L, Pina, IL, et al. Increasing Diversity in Clinical Trials. Current Problems in Cardiology. 2019; 44(5):148-175.
4. Centers for Disease Control and Prevention. Social Determinants of Health: Know What Affects Health. Available at: https://www.cdc.gov/socialdeterminants/index.htm. Accessed August 20, 2020.
5. Turner, A. The Business Case for Racial Equity. WK Kellogg Foundation. Available at: http://ww2.wkkf.org/2018/bcfre/BCRE-National-Report.pdf, Accessed February 13, 2020.
6. American Public Health Association. Health Equity. Available at: https://www.apha.org/topics-and-issues/health-equity. Accessed February 13, 2020.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com
Eric Althoff Head, US Corp & Country External Comms, Global Media & Corp Communications +1 646 438 4335 eric.althoff@novartis.com	Jamie Bennett Director, US Media Relations +1 862 217 3976 jamie.bennett@novartis.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-us-foundation-commits-25m-to-improve-health-equity-by-reducing-health-disparities-in-the-us-301132564.html

SOURCE Novartis US Corporate

FAQ

What is the purpose of Novartis US Foundation's USD 25 million commitment?

The commitment aims to address health inequities in underserved communities and enhance diversity in clinical trials.

How does Novartis Foundation plan to increase diversity in clinical trials?

The foundation intends to collaborate with partners and support industry-wide programs to improve diversity through systemic and policy-driven solutions.

What issues are highlighted by Novartis regarding health disparities?

The foundation emphasizes barriers like mistrust in healthcare, lack of understanding of clinical trial processes, and time/resource constraints.

What percentage of US clinical trial participants were African Americans in 2019?

In 2019, African Americans made up only 9% of clinical trial participants, despite being 13.5% of the US population.

What previous funding initiatives has the Novartis US Foundation undertaken?

Before this commitment, the foundation invested over USD 10 million to develop partnerships aimed at overcoming barriers to healthcare.